117 related articles for article (PubMed ID: 22445286)
1. Discovery and evaluation of spirocyclic derivatives as antagonists of the neuropeptide Y5 receptor.
Fichtner M; Lee E; Tomlinson E; Scott D; Cornelius P; Patterson TA; Carpino PA
Bioorg Med Chem Lett; 2012 Apr; 22(8):2738-43. PubMed ID: 22445286
[TBL] [Abstract][Full Text] [Related]
2. Novel orally active NPY Y5 receptor antagonists: Synthesis and structure-activity relationship of spiroindoline class compounds.
Sakamoto T; Moriya M; Tsuge H; Takahashi T; Haga Y; Nonoshita K; Okamoto O; Takahashi H; Sakuraba A; Hirohashi T; Shibata T; Kanno T; Ito J; Iwaasa H; Gomori A; Ishihara A; Fukuroda T; Kanatani A; Fukami T
Bioorg Med Chem; 2009 Jul; 17(14):5015-26. PubMed ID: 19525116
[TBL] [Abstract][Full Text] [Related]
3. Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.
Takahashi T; Haga Y; Sakamoto T; Moriya M; Okamoto O; Nonoshita K; Shibata T; Suga T; Takahashi H; Hirohashi T; Sakuraba A; Gomori A; Iwaasa H; Ohe T; Ishihara A; Ishii Y; Kanatani A; Fukami T
Bioorg Med Chem Lett; 2009 Jul; 19(13):3511-6. PubMed ID: 19464889
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of new arylsulfonamidomethylcyclohexyl derivatives as human neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
Moreno A; Pérez S; Galiano S; Juanenea L; Erviti O; Frígola C; Aldana I; Monge A
Eur J Med Chem; 2004 Jan; 39(1):49-58. PubMed ID: 14987833
[TBL] [Abstract][Full Text] [Related]
5. Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect.
Sato N; Ando M; Ishikawa S; Jitsuoka M; Nagai K; Takahashi H; Sakuraba A; Tsuge H; Kitazawa H; Iwaasa H; Mashiko S; Gomori A; Moriya R; Fujino N; Ohe T; Ishihara A; Kanatani A; Fukami T
J Med Chem; 2009 May; 52(10):3385-96. PubMed ID: 19459652
[TBL] [Abstract][Full Text] [Related]
6. Discovery and structure-activity relationship of a novel spirocarbamate series of NPY Y5 antagonists.
Leslie CP; Bentley J; Biagetti M; Contini S; Di Fabio R; Donati D; Genski T; Guery S; Mazzali A; Merlo G; Pizzi DA; Sacco F; Seri C; Tessari M; Zonzini L; Caberlotto L
Bioorg Med Chem Lett; 2010 Oct; 20(20):6103-7. PubMed ID: 20813523
[TBL] [Abstract][Full Text] [Related]
7. Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist.
Haga Y; Sakamoto T; Shibata T; Nonoshita K; Ishikawa M; Suga T; Takahashi H; Takahashi T; Takahashi H; Ando M; Murai T; Gomori A; Oda Z; Kitazawa H; Mitobe Y; Kanesaka M; Ohe T; Iwaasa H; Ishii Y; Ishihara A; Kanatani A; Fukami T
Bioorg Med Chem; 2009 Oct; 17(19):6971-82. PubMed ID: 19720539
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel orally active ureido NPY Y5 receptor antagonists.
Li G; Stamford AW; Huang Y; Cheng KC; Cook J; Farley C; Gao J; Ghibaudi L; Greenlee WJ; Guzzi M; van Heek M; Hwa JJ; Kelly J; Mullins D; Parker EM; Wainhaus S; Zhang X
Bioorg Med Chem Lett; 2008 Feb; 18(3):1146-50. PubMed ID: 18160282
[TBL] [Abstract][Full Text] [Related]
9. A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice.
Ishihara A; Kanatani A; Mashiko S; Tanaka T; Hidaka M; Gomori A; Iwaasa H; Murai N; Egashira S; Murai T; Mitobe Y; Matsushita H; Okamoto O; Sato N; Jitsuoka M; Fukuroda T; Ohe T; Guan X; MacNeil DJ; Van der Ploeg LH; Nishikibe M; Ishii Y; Ihara M; Fukami T
Proc Natl Acad Sci U S A; 2006 May; 103(18):7154-8. PubMed ID: 16636293
[TBL] [Abstract][Full Text] [Related]
10. Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine.
Mashiko S; Ishihara A; Iwaasa H; Moriya R; Kitazawa H; Mitobe Y; Ito J; Gomori A; Matsushita H; Takahashi T; MacNeil DJ; Van der Ploeg LH; Fukami T; Kanatani A
Obesity (Silver Spring); 2008 Jul; 16(7):1510-5. PubMed ID: 18421274
[TBL] [Abstract][Full Text] [Related]
11. Comparison of independent and combined chronic anti-obese effects of NPY Y2 receptor agonist, PYY(3-36), and NPY Y5 receptor antagonist in diet-induced obese mice.
Moriya R; Mashiko S; Ishihara A; Takahashi T; Murai T; Ito J; Mitobe Y; Oda Z; Iwaasa H; Takehiro F; Kanatani A
Peptides; 2009 Jul; 30(7):1318-22. PubMed ID: 19394383
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity.
Torrens A; Mas J; Port A; Castrillo JA; Sanfeliu O; Guitart X; Dordal A; Romero G; Fisas MA; Sánchez E; Hernández E; Pérez P; Pérez R; Buschmann H
J Med Chem; 2005 Mar; 48(6):2080-92. PubMed ID: 15771450
[TBL] [Abstract][Full Text] [Related]
13. Obesity and the central nervous system.
Mifflin SW; Strack A
J Physiol; 2007 Sep; 583(Pt 2):423. PubMed ID: 17766646
[No Abstract] [Full Text] [Related]
14. An insurmountable NPY Y5 receptor antagonist exhibits superior anti-obesity effects in high-fat diet-induced obese mice.
Fukasaka Y; Nambu H; Tanioka H; Obata A; Tonomura M; Okuno T; Yukioka H
Neuropeptides; 2018 Aug; 70():55-63. PubMed ID: 29801968
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of a series of pyrrolo[3,2-d]pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists.
Norman MH; Chen N; Chen Z; Fotsch C; Hale C; Han N; Hurt R; Jenkins T; Kincaid J; Liu L; Lu Y; Moreno O; Santora VJ; Sonnenberg JD; Karbon W
J Med Chem; 2000 Nov; 43(22):4288-312. PubMed ID: 11063624
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of substituted 2-cyclohexyl-4-phenyl-1H-imidazoles: potent and selective neuropeptide Y Y5-receptor antagonists.
Blum CA; Zheng X; De Lombaert S
J Med Chem; 2004 Apr; 47(9):2318-25. PubMed ID: 15084130
[TBL] [Abstract][Full Text] [Related]
17. Optimization of oxadiazole derivatives with a spirocyclic cyclohexane structure as novel GPR119 agonists.
Harada K; Mizukami J; Watanabe T; Mori G; Ubukata M; Suwa K; Fukuda S; Negoro T; Sato M; Inaba T
Bioorg Med Chem Lett; 2019 Aug; 29(16):2100-2106. PubMed ID: 31288965
[TBL] [Abstract][Full Text] [Related]
18. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.
Erondu N; Gantz I; Musser B; Suryawanshi S; Mallick M; Addy C; Cote J; Bray G; Fujioka K; Bays H; Hollander P; Sanabria-Bohórquez SM; Eng W; Långström B; Hargreaves RJ; Burns HD; Kanatani A; Fukami T; MacNeil DJ; Gottesdiener KM; Amatruda JM; Kaufman KD; Heymsfield SB
Cell Metab; 2006 Oct; 4(4):275-82. PubMed ID: 17011500
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of new hydrazide derivatives as neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
Juanenea L; Galiano S; Erviti O; Moreno A; Pérez S; Aldana I; Monge A
Bioorg Med Chem; 2004 Sep; 12(17):4717-23. PubMed ID: 15358298
[TBL] [Abstract][Full Text] [Related]
20. The identification of a series of novel, soluble non-peptidic neuropeptide Y Y2 receptor antagonists.
Lunniss GE; Barnes AA; Barton N; Biagetti M; Bianchi F; Blowers SM; Caberlotto LL; Emmons A; Holmes IP; Montanari D; Norris R; Puckey GV; Walters DJ; Watson SP; Willis J
Bioorg Med Chem Lett; 2010 Dec; 20(24):7341-4. PubMed ID: 21074426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
